Federal Policy
OIG Flags 10 Drug Codes for Medicare Part B Price Substitution
OIG compared Medicare Part B average sales prices (ASPs) with average manufacturer prices (AMPs) for the second quarter of 2026, as required under the Social Security Act. OIG found that 10 drug codes exceeded the AMP by more than 5 percent for two consecutive quarters or three of the previous four quarters, meeting CMS's criteria for price substitution. OIG is sending these 10 drug codes to CMS for review to determine whether to substitute lower payment rates to limit excessive Part B drug payments.
Why it mattersProviders and health plans administering Medicare Part B drugs could see reimbursement rates reduced for the flagged drug codes if CMS pursues price substitution.